Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Status:
Withdrawn
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with
hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected
into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE
in many patients.
A new treatment using a specialized radiation procedure called Stereotactic ablative body
radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation
treatments to be focused more precisely, and be delivered more accurately than with older
treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is
better for you and your liver cancer.